Phaseline

Companies › Aura Biosciences

Aura Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
belzupacap sarotalocan
Complement 3 inhibitor; intravitreal antibody targeting complement cascade
COMPLEMENT3Phase 3Choroidal MelanomaNov 2027
AU-011
anti-PGLYRP4 antibody-drug conjugate
PGLYRP4Phase 2Eye Cancer; Non-muscle-invasive Bladder CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06643884AU-011Phase 2Eye CancerOncologyNov 2026
NCT05483868AU-011Phase 1Non-muscle-invasive Bladder CancerOncologyMar 2027
NCT06007690belzupacap sarotalocanPhase 3Choroidal MelanomaOncologyNov 2027

From the company's SEC filings

Cash of $42m on 2026-09-30; operating cash outflow about $119m a year; runway about 4 months at that burn, to Feb 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

COMPLEMENT3 (1) PGLYRP4 (1)

Companies with the same targets

–

Companies built like this

Dogwood Therapeutics Atossa Therapeutics Curis Can-Fite BioPharma LeonaBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.